Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?

Our new paper published in the European Journal of Cancer highlight current limitations regarding the efficacy of TTFs in oncology.

Jul 11 • Sahar van Waalwijk and Timothée Olivier

12

1

EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial

It’s my pleasure to welcome back Sahar Van Waalwijk, who covers an important topic following an unusual development.

Jul 9 • Sahar van Waalwijk

17

3

May 2026

Additional Insights Into Early Daraxonrasib Data

Let’s take a deep dive into the early-phase data on daraxonrasib in patients with metastatic pancreatic cancer, just published in the New England…

May 19

22

2

World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial

In two back-to-back essays, we and our counterparts reach opposing conclusions regarding the DART trial and broad reimbursement of dual immunotherapy.

May 16 • Timothée Olivier and Sahar van Waalwijk

15

3

RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?

A pharmacological breakthrough might not always revolutionize patients' outcomes.

May 4 • Timothée Olivier

23

2

1

April 2026

An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.

Our new paper, with Sunny Kim and Vinay Prasad, is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering…

Apr 14 • Timothée Olivier

16

1

The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.

The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse.

Apr 12 • Sahar van Waalwijk and Timothée Olivier

23

3

March 2026

An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.

Reports from HTA bodies may contain key data absent from trial publications and constitute a unique source for trial appraisal.

Mar 25 • Timothée Olivier

14

2

1

My IQWiG lecture in Cologne! What a great audience and team!

I was invited by IQWiG to give a lecture in Cologne, Germany. The talk was followed by fascinating discussions with the IQWiG team about methodology in…

Mar 23 • Timothée Olivier

14

1

49:29

The BREAKING-ICE App© V2.0 is out! Enjoy automated explorations and a new companion KM digitizer App.

Discover “Automated” modes. Discover the brand-new, user-friendly, Assistant-KM-BREAKING-ICE© app, which allows you to extract and directly explore data…

Mar 21 • Timothée Olivier

14

1

The Imbalance of NCCN Guidelines: Quick to Implement, Slow to Let Go

It’s my great pleasure to welcome Christopher Rios to The Oncology Shot.

Mar 9 • Christopher Rios

16

1

1

February 2026

Critical Appraisal in Breast Cancer: The Essentials in 30 Minutes.

Here is a live recording of a talk I gave at SAMO on 27 February 2026.

Feb 28 • Timothée Olivier

15

1

33:54